Please upgrade your browser.
"Cipla will launch ''sorafenib tosylate'' under the brand Soranib, the generic version of Nexavar at less than 1/10th of Bayer''s price of Rs 2.8 lakh for a month''s treatment," Cipla Joint Managing Director Amar Lulla told PTI over telephone.
The rationing body NICE has since refused to approve ten such drugs. Experts say the rulings cut short up to 20,000 lives.
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival
A phase III trial of bevacizumab combined with interferon alfa-2a (IFN) showed significant improvements in progression-free survival (PFS) in metastatic renal cell carcinoma (mRCC).
The researchers found that survivors of childhood cancers face health risks that shorten their life span by about 10 years on average. The loss in life expectancy varied for different types of cancer. Survivors of kidney cancer died about 4 years earlier . . .
Life-saving cancer drugs are still not available on the NHS nearly 18 months after the Government promised to improve access to vital medicines, the Conservatives claim.
In addition to our ongoing Phase 3 clinical trial of once-daily, oral tivozanib in patients with advanced RCC, we are currently conducting multiple clinical trials of tivozanib . . .
The Onconeural Antigen cdr2 Is a Novel APC/C Target that Acts in Mitosis to Regulate C-Myc Target Genes in Mammalian Tumor Cells
Cdr2 is a tumor antigen expressed in a high percentage of breast and ovarian tumors and is the target of a naturally occurring tumor immune response in patients with paraneoplastic cerebellar degeneration, but little is known of its regulation or function in cancer cells. Here we find that cdr2 is cell cycle regulated in tumor cells with protein levels peaking in mitosis.
Studying patients with kidney cancer, a team of researchers at Washington University School of Medicine in St. Louis has identified a pair of proteins excreted in the urine that could lead to earlier and more accurate diagnosis of the disease.
In this review, we discuss the use of molecularly-targeted kinase inhibitors in the treatment of renal-cell carcinoma and identify the next generation of kinase inhibitors that show promise for treatment.
The trial will determine whether BNC105 is effective in the treatment of progressive metastaticrenal cell carcinoma, either in combination with or following Afinitor (also known asEverolimus) treatment in patients who have disease progression following treatment withtyrosine kinase inhibitors such as Sutent or Nexavar.
|Powered by NeonCRM|